Published in J Infect Dis on June 07, 2005
Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol (2007) 2.96
A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS One (2008) 1.92
Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Antimicrob Agents Chemother (2006) 1.76
Drug discovery for malaria: a very challenging and timely endeavor. Curr Opin Chem Biol (2007) 1.51
A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS One (2007) 1.38
CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos (2006) 1.30
A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol Sci (2012) 1.02
Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles. J Med Chem (2010) 1.00
The diamidine DB75 targets the nucleus of Plasmodium falciparum. Malar J (2009) 0.96
Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2009) 0.93
Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission. Cochrane Database Syst Rev (2014) 0.91
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev (2015) 0.90
Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozoal agents. Eur J Med Chem (2008) 0.89
A new in vivo screening paradigm to accelerate antimalarial drug discovery. PLoS One (2013) 0.86
Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo. PLoS One (2011) 0.86
Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles. Bioorg Med Chem (2010) 0.84
Interactions of DB75, a novel antimalarial agent, with other antimalarial drugs in vitro. Antimicrob Agents Chemother (2008) 0.75
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet (2007) 19.04
WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet (2004) 9.27
Epidemiology of drug-resistant malaria. Lancet Infect Dis (2002) 7.59
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis (2008) 4.68
Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 4.57
Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg (2007) 4.51
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother (2003) 4.01
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med (2006) 3.83
Sensitive and inexpensive molecular test for falciparum malaria: detecting Plasmodium falciparum DNA directly from heat-treated blood by loop-mediated isothermal amplification. Clin Chem (2005) 3.75
Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest (2008) 3.59
I would like to propose that the American Society of Tropical Medicine and Hygiene change its name. Am J Trop Med Hyg (2003) 3.30
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A (2011) 3.23
A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis (2005) 3.15
Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis (2004) 2.82
Central role of the spleen in malaria parasite clearance. J Infect Dis (2002) 2.80
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2009) 2.66
High-throughput pooling and real-time PCR-based strategy for malaria detection. J Clin Microbiol (2009) 2.52
Unheard Alaska: culturally anchored participatory action research on sobriety with Alaska Natives. Am J Community Psychol (2004) 2.51
Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet (2010) 2.48
An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.47
Antimalarial drug resistance of Plasmodium falciparum in India: changes over time and space. Lancet Infect Dis (2011) 2.47
Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS (2006) 2.34
Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J Immunol (2004) 2.33
Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J (2009) 2.33
The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hyg (2004) 2.32
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother (2003) 2.26
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. Clin Infect Dis (2012) 2.19
Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria. Blood (2002) 2.19
Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother (2004) 2.17
Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J (2005) 2.15
Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg (2003) 2.10
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis (2010) 2.08
Risk, resilience, and natural recovery: a model of recovery from alcohol abuse for Alaska Natives. Addiction (2007) 2.03
A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg (2004) 2.02
Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem (2002) 2.01
The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS (2004) 2.01
Hematologic and clinical indices of malaria in a semi-immune population of western Thailand. Am J Trop Med Hyg (2004) 1.99
Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog (2010) 1.96
Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet (2005) 1.94
Comparison of real-time PCR and microscopy for malaria parasite detection in Malawian pregnant women. Malar J (2010) 1.94
Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell (2003) 1.94
Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One (2009) 1.93
Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis (2005) 1.88
Malaria diagnosis: a brief review. Korean J Parasitol (2009) 1.86
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem (2010) 1.84
Human CHN1 mutations hyperactivate alpha2-chimaerin and cause Duane's retraction syndrome. Science (2008) 1.84
"Tied together like a woven hat:" Protective pathways to Alaska native sobriety. Harm Reduct J (2004) 1.79
Molecular malaria epidemiology: mapping and burden estimates for the Democratic Republic of the Congo, 2007. PLoS One (2011) 1.78
pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. Am J Trop Med Hyg (2005) 1.76
Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Antimicrob Agents Chemother (2006) 1.76
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob Agents Chemother (2009) 1.73
High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg (2008) 1.72
Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet (2004) 1.71
Keys to success for a school-based malaria control program in primary schools in Thailand. Parasitol Int (2006) 1.71
Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother (2005) 1.69
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis (2011) 1.66
Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis (2010) 1.65
Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin Infect Dis (2003) 1.61
Extended linkage disequilibrium surrounding the hemoglobin E variant due to malarial selection. Am J Hum Genet (2004) 1.61
Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res (2002) 1.61
Radon and skin cancer in southwest England: an ecologic study. Epidemiology (2012) 1.61
Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J (2009) 1.59
Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol (2002) 1.59
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop (2004) 1.58
Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis (2008) 1.58
Host response to malaria during pregnancy: placental monocyte recruitment is associated with elevated beta chemokine expression. J Immunol (2003) 1.55
Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg (2003) 1.54
The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol (2003) 1.53
The clinical efficacy of artemether/lumefantrine (Coartem). Malar J (2009) 1.52
Inhibitory activity of marine sponge-derived natural products against parasitic protozoa. Mar Drugs (2010) 1.52
Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol (2008) 1.52
Prevalence distribution and risk factors for Schistosoma hematobium infection among school children in Blantyre, Malawi. PLoS Negl Trop Dis (2009) 1.51
Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U S A (2002) 1.50
The effect of timing and frequency of Plasmodium falciparum infection during pregnancy on the risk of low birth weight and maternal anemia. Trans R Soc Trop Med Hyg (2010) 1.49
Synthesis and antiprotozoal activity of aza-analogues of furamidine. J Med Chem (2003) 1.49
Minority-variant pfcrt K76T mutations and chloroquine resistance, Malawi. Emerg Infect Dis (2007) 1.48
Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis (2009) 1.48
Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies. Antimicrob Agents Chemother (2006) 1.48
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One (2010) 1.48
Activities of psilostachyin A and cynaropicrin against Trypanosoma cruzi in vitro and in vivo. Antimicrob Agents Chemother (2013) 1.47
Natural human humoral response to salivary gland proteins of Anopheles mosquitoes in Thailand. Acta Trop (2006) 1.47